欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (2): 265-271.doi: 10.12092/j.issn.1009-2501.2025.02.014

• 综述与讲座 • 上一篇    下一篇

基于海马FXR调控CREB-BDNF信号通路影响抑郁症的研究进展

何慧,郭明亮,冉立成,王亚军   

  1. 甘肃中医药大学针灸推拿学院,兰州  730000,甘肃
  • 收稿日期:2024-02-18 修回日期:2024-03-28 出版日期:2025-02-26 发布日期:2025-02-05
  • 通讯作者: 王亚军,男,教授,博士生导师,研究方向:针刺治疗情志病的机制及临床研究。 E-mail: tangniao2008@126.com
  • 作者简介:何慧,女,硕士研究生,研究方向:针刺治疗情志病的机制研究。 E-mail: 1106908592@qq.com
  • 基金资助:
    国家自然科学基金(82160936)

Research progress on the effect of hippocampal FXR regulation of CREB-BDNF signaling pathway on depression

HE Hui, GUO Mingliang, RAN Licheng, WANG Yajun   

  1. Gansu University of Chinese Medicine, Acupuncture and Tuina School, Lanzhou 730000, Gansu, China
  • Received:2024-02-18 Revised:2024-03-28 Online:2025-02-26 Published:2025-02-05

摘要:

抑郁症是一种以心境障碍为主要特征的精神类疾病,对人类的身心健康构成了重大的威胁。近年来,法尼醇X受体(farnesoid X receptor,FXR)已被发现在大脑海马体等脑区中表达,并与抑郁症的发病密切相关。其还可影响下游靶标环磷酸腺苷反应元件结合蛋白(cAMP response element binding protein,CREB)-脑源性神经营养因子(brain-derived-neurotrophic factor,BDNF)信号通路,有望作为治疗抑郁症的新靶点。本文分析海马FXR如何调控CREB-BDNF信号通路,并总结与抑郁症发病机制相关的最新研究进展,以期为抑郁症的药物研发和临床治疗提供精准靶向的思路。

关键词: FXR, CREB-BDNF, 信号通路, 抑郁症

Abstract:

Depression is a mental disorder characterized by mood disturbances that pose a significant threat to human mental and physical health. In recent years, the farnesoid X receptor (FXR) has been found to be expressed in brain regions such as the hippocampus and is closely related to the onset of depression. It can also affect the downstream target cAMP response element binding protein (CREB)-brain-derived neurotrophic factor (BDNF) signaling pathway, holding promise as a new target for the treatment of depression. This article analyzes how hippocampal FXR regulates the CREB-BDNF signaling pathway and summarizes the latest research progress related to the pathogenesis of depression, with the aim of providing precise targeted ideas for the drug development and clinical treatment of depression.

Key words: FXR, CREB-BDNF, signaling pathway, depression

中图分类号: